ArticleJournal of translational medicine2026
Targeting cell membrane sphingolipids: a novel ceramide analog CeY-B1 inhibits migration and invasion in cervical cancer cells.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCervical cancer remains one of the leading causes of cancer-related mortality among women worldwide. The prognosis of cervical cancer is poor due to persistent chemotherapy resistance and repeated recurrence; therefore the development of new drugs is crucial.
methodsCeY-B1 is a ceramide analogue that we synthesized and evaluated in cervical cancer cell lines using cell viability assays, colony formation, migration, invasion, apoptosis, and cell cycle assays. We performed lipidomics analysis to assess changes in sphingolipid metabolism after CeY-B1 treatment. Furthermore, we conducted network pharmacology analysis to predict potential molecular targets and signaling pathways. We further detected key signaling proteins using qPCR and Western blot analysis. Finally, we evaluated the antitumor efficacy of CeY-B1 in a subcutaneous xenograft mouse model.
resultsIn this study, we synthesized a ceramide analog CeY-B1, which inhibited the proliferation, migration, and invasion of cervical cancer cells, induced apoptosis and cell cycle arrest, and suppressed tumor growth in a xenograft mouse model. Lipidomics results showed that CeY-B1 treatment led to the accumulation of specific ceramide species, especially Cer(t18:0/24:1), Cer(t18:0/24:0), and Cer(d18:1/24:0(2OH)), indicating that the sphingolipid signaling pathway was activated. Network pharmacology revealed 78 common target genes between CeY-B1 and cervical cancer, and identified enriched pathways including PI3K/AKT signaling, MAPK signaling, and oxidative stress response. Mechanistic studies showed that CeY-B1 upregulated ASK1 and phosphorylated JNK while downregulated Bcl-2. Lipid sequencing and network pharmacology showed that the ASK1-JNK pathway was activated and the PI3K/AKT pathway was inhibited in the sphingolipid signaling cascade, both of which contribute to cell apoptosis.
conclusionsThese findings support the potential of CeY-B1 as a novel therapeutic agent for cervical cancer, via the regulation of ceramide metabolism, cell survival, and apoptotic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.